Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Fig. 4

XPO1 inhibitor KPT-335 induces nuclear accumulation of P53 in in neuroblastoma cells. A Immunofluorescence images of nuclear P53 in SK-N-BE(2) and SH-SY5Y after KPT-335 treatment. B and C Degradation rate of P53 mRNA in SK-N-BE (2) and SH-SY5Y after KPT-335 treatment. D Degradation rate of P53 protein in SK-N-BE (2) and SH-SY5Y after KPT-335 treatment. E Western blot analysis of P53 levels in nucleus and cytoplasm of SK-N-BE (2) and SH-SY5Y after KPT-335 treatment. Data presented as mean ± SD (n = 3). * P < 0.05, ** P < 0.01

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us